By contrast, the same analysis between the 468 metastatic samples of non‐IBC patients and the 101 IBC samples identified only one gene differentially altered (HER2), indicating that IBC and metastatic non‐IBC samples are not so different at a genomic level when compared head‐on. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.